MeSH D006960 - primary hyperoxaluria
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Lumasiran | Oxlumo | 2020-11-19 | $156.207 M | Q4/23-Q3/24 | |
| Novo Nordisk | Nedosiran | Rivfloza | 2035-10-09 | 2023-09-29 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
20%1/5
Phase 3
67%2/3
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use